In 1,446 patients hospitalized with COVID-19, hydroxychloroquine administration was not associated with significantly higher or lower risk of death.
Geleris, J. et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine (2020). DOI: 10.1056/NEJMoa2012410
7 May 2020
The researchers performed an observational study of 1,446 consecutive patients who were admitted to a large medical centre in New York City between March and April 2020. Time to intubation or death was compared between patients who received hydroxychloroquine and those who did not. Patients treated with hydroxychloroquine were more severely ill to begin with and received 600 mg hydroxychloroquine twice on day 1, then 400 mg daily for a variable number of days. Ultimately, no significant association was found between hydroxychloroquine administration and intubation or death. The study does not rule out benefit or harm from hydroxychloroquine use due to its observational design. However, the results do not support using this medication for treatment of COVID-19 outside of randomized clinical trials.
Summary by: Sivakami Mylvaganam